PMID- 38135295 OWN - NLM STAT- MEDLINE DCOM- 20240229 LR - 20240229 IS - 1747-4094 (Electronic) IS - 1747-4094 (Linking) VI - 17 IP - 1-3 DP - 2024 Jan-Mar TI - Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis. PG - 67-76 LID - 10.1080/17474086.2023.2298732 [doi] AB - OBJECTIVES: This study evaluated the benefits and risks of patients with refractory or relapsed acute lymphocytic leukemia (R/R ALL) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and blinatumomab. METHODS: PubMed, Web of Science, Embase, and the Cochrane Library were searched for relevant studies. RESULTS: The pooled complete remission (CR) rate and minimal residual disease (MRD) negative rate were 48%, 31% for blinatumomab, and 86% and 80% for CAR T-cell therapy. CONCLUSIONS: The CAR T-cell therapy group exhibited a higher likelihood of CR rate than the blinatumomab group in every analysis regardless of adjustment subgroups. CAR T-cell therapy was associated with a significantly prolonged overall survival (OS) and relapse-free survival (RFS) compared with blinatumomab (2-year OS 55% vs 25%; 2-year RFS 40% vs 22%). CAR T-cell therapy was more effective for achieving CR and bridging to allogeneic hematopoietic stem cell transplantation (allo-SCT) than blinatumomab (2-year OS 75% vs. 57%). An emerging role for blinatumomab is as a bridging agent pre-SCT, and for patients who achieve an MRD-negative state pre-SCT, post-SCT outcomes are expected to be the same as CAR-T. For adverse effects (AEs), blinatumomab was associated with a lower rate of grade >/=3 hematological toxicity, CRS, and neurological events. FAU - Zhai, Yixin AU - Zhai Y AUID- ORCID: 0000-0002-0968-1207 AD - Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Hong, Ju AU - Hong J AD - Tianjin Key Lab of Ophthalmology and Visual Science, Tianjin Eye Hospital, Tianjin, China. FAU - Wang, Jinhuan AU - Wang J AD - Department of Oncology, Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Jiang, Yanan AU - Jiang Y AD - Department of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China. FAU - Wu, Wenqi AU - Wu W AD - Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Lv, Yangyang AU - Lv Y AD - Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Guo, Jing AU - Guo J AD - Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Tian, Linyan AU - Tian L AD - Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Sun, Huimeng AU - Sun H AD - Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Li, Yuhang AU - Li Y AD - Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Li, Cheng AU - Li C AD - Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Zhan, Hongjie AU - Zhan H AD - Department of Gastroenterology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Zhao, Zhigang AU - Zhao Z AD - Department of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20240104 PL - England TA - Expert Rev Hematol JT - Expert review of hematology JID - 101485942 RN - 4FR53SIF3A (blinatumomab) RN - 0 (Antibodies, Bispecific) RN - 0 (Antigens, CD19) SB - IM MH - Humans MH - Immunotherapy, Adoptive/adverse effects MH - *Hematopoietic Stem Cell Transplantation MH - *Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy MH - *Antibodies, Bispecific/adverse effects MH - Recurrence MH - Antigens, CD19 OTO - NOTNLM OT - ALL OT - Blinatumomab OT - CAR T OT - acute lymphoblastic leukemia OT - chimeric antigen receptor T cell therapy OT - relapsed/refractory acute lymphoblastic leukemia EDAT- 2023/12/23 12:42 MHDA- 2024/02/29 06:43 CRDT- 2023/12/22 20:43 PHST- 2024/02/29 06:43 [medline] PHST- 2023/12/23 12:42 [pubmed] PHST- 2023/12/22 20:43 [entrez] AID - 10.1080/17474086.2023.2298732 [doi] PST - ppublish SO - Expert Rev Hematol. 2024 Jan-Mar;17(1-3):67-76. doi: 10.1080/17474086.2023.2298732. Epub 2024 Jan 4.